86604-78-6

Basic information

• Product Name: 3,5-Dimethyl-4-methoxy-2-pyridinemethanol
• Synonyms: ((4-Methoxy-3,5-dimethyl)-2-pyridinyl)methanol;4-methoxy-3,5-dimethyl-2-pyridylmethanol;PYRMETHYLALCOHOL;2-HYDROXYMETHYL-4-METHOXY-3,5-DIMETHYLPYRIDINE;2-HYDROXYMETHYL-3,5-DIMETHYL-4-METHOXY PYRIDINE;3,5-DIMETHYL-2-HYDROXYMETHYL-4-METHOXYPYRIDINE;3,5-DIMETHYL-4-METHOXY-2-PYRIDINE METHANOL;4-METHOXY-3,5-DIMETHYL-2-HYDROXYMETHYL PYRIDINE
• CAS NO: 86604-78-6
• Molecular Formula: C9H13NO2
• Molecular Weight: 167.21
• EINECS: 289-258-5
• Product Categories: Aromatic alcohols and diols;Pyridines derivates;C9 to C46;Heterocyclic Building Blocks;Pyridines;Pharmaceutical intermediates;OLED materials,pharm chemical,electronic;Heterocycle-Pyridine series
• Mol File: 86604-78-6.mol
• Article Data: 17

Chemical Properties

• Melting Point: 56.5-60.5 °C(lit.)
• Boiling Point: 289.1 °C at 760 mmHg
• Flash Point: 128.7 °C
• Appearance: /
• Density: 1.092 g/cm³
• Vapor Pressure: 0.00104mmHg at 25°C
• Refractive Index: 1.528
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: Chloroform (Slightly)
• PKA: 13.27±0.10(Predicted)
• CAS DataBase Reference: 3,5-Dimethyl-4-methoxy-2-pyridinemethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-Dimethyl-4-methoxy-2-pyridinemethanol(86604-78-6)
• EPA Substance Registry System: 3,5-Dimethyl-4-methoxy-2-pyridinemethanol(86604-78-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 86604-78-6(Hazardous Substances Data)

Usage

Uses

(4-Methoxy-3,5-dimethylpyridin-2-yl)methanol can be used as wear-resistant rubber.

General Description

4-Methoxy-3,5-dimethyl-2-pyridinemethanol is a pyridine derivative.

InChI:InChI=1/C9H13NO2/c1-6-4-10-8(5-11)7(2)9(6)12-3/h4,11H,5H2,1-3H3

Upstream product

• 130000-78-1 (4-methoxy-3,5-dimethylpyridin-2-yl)methanamine 
• 75-09-2 dichloromethane 
• 91219-89-5 3,5-dimethyl-4-methoxypyridine 1-oxide 
• 77-78-1 dimethyl sulfate 
• 86604-75-3 2-(chloromethyl)-4-methoxy-3,5-dimethylpyridine hydrochloride 
• 67-56-1 methanol 
• 73590-58-6 omeprazole 
• 150054-50-5 4-chloro-2-hydroxymethyl-3,5-dimethylpyridine 
• 187222-15-7 N-benzyl-2-ethoxycarbonyl-3,5-dimethyl-4-pyridone 
• 187222-16-8 2-Ethoxycarbonyl-3,5-dimethyl-4(1H)-pyridone 
• 187222-13-5 3,5-Dimethyl-2-ethoxycarbonyl-4-pyrone 
• 187222-12-4 3,5-dimethyl-4-oxo-4H-pyran-2-carboxylic acid 
• 187222-17-9 4-Chloro-2-ethoxycarbonyl-3,5-Lutidine 
• 187222-11-3 1-ethoxy-2-methylpent-1-en-3-one 

Downstream Products

• 110464-72-7 4-methoxy-3,5-dimethyl-2-pyridinecarboxaldehyde 
• 220757-73-3 2-hydroxymethyl-3,5-dimethylpyridin-4-ol 
• 1025112-89-3 {(1R,3S)-3-hexadecanoylamino-1-hydroxy-4-[4-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethoxy)-phenyl]-butyl}-phosphonic acid dimethyl ester 
• 1025112-66-6 {(1S,3S)-3-hexadecanoylamino-1-hydroxy-4-[4-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethoxy)-phenyl]-butyl}-phosphonic acid dimethyl ester 
• 780752-32-1 4-methoxy-3,5-dimethyl-2-pyridinemethyl bromide 
• 1196886-10-8 (E)-N-(4-(benzyloxy)-6-chloro-2-(methylthio)pyrimidin-5-yl)-N-(3-(4-methoxy-3,5-dimethylpyridin-2-yl)allyl)-4-methylbenzenesulfonamide 
• 1196886-12-0 4-(benzyloxy)-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-2-(methylthio)-5-tosyl-5H-pyrrolo[3,2-d]pyrimidine 
• 1196886-14-2 4-(benzyloxy)-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-2-(methylsulfonyl)-5-tosyl-5H-pyrrolo[3,2-d]pyrimidine 
• 1196886-17-5 7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-2-(methylsulfonyl)-5-tosyl-5H-pyrrolo[3,2-d]pyrimidin-4-ol 
• 1196886-19-7 2-amino-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-5-tosyl-5H-pyrrolo[3,2-d]pyrimidin-4-ol 
• 1099653-07-2 3-(4-methoxy-3,5-dimethylpyridin-2-yl)-1-phenylpropan-1-one 
• 73590-60-0 2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole 
• 104916-41-8 3,5-dimethyl-4-methoxy-2-cyanopyridine 
• 1544041-48-6 1-(4-chlorophenyl)-3-(4-methoxy-3,5-dimethylpyridin-2-yl)propan-1-one 

Relevant articles and documents

Preparation method of omeprazole intermediate

The invention relates to a preparation method of an omeprazole intermediate. According to the method, Nmethoxy-4-methoxy3, 5-dimethyl pyridinium is used as a raw material, metal ions are added as an additive, under the action of persulfate, 2-hydroxymethyl- 3, 5-dimethyl -4methoxypyridine is efficiently prepared, and then the 2-hydroxymethyl -3, 5-dimethyl- 4-methoxypyridine is further converted into 2-chloromethyl -3, 5-dimethyl- 4methoxypyridine hydrochloride. According to the method, the conversion rate, the yield and the quality of the 2-hydroxymethyl- 3, 5-dimethyl -4-methoxy pyridine areremarkably improved, so that the purity of the 2-chloromethyl- 3, 5-dimethyl- 4-methoxy pyridine hydrochloride obtained by further reaction is improved, the impurity content is reduced, the product yield and the production efficiency can be effectively improved, the production capacity is improved, and the production cost is reduced.

Slow, spontaneous degradation of lansoprazole, omeprazole and pantoprazole tablets: Isolation and structural characterization of the toxic antioxidants 3H-benzimidazole-2-thiones

The spontaneous degradation of lansoprazole, omeprazole and pantoprazole tablets upon long-term and forced storage conditions was determined by high performance liquid chromatography (HPLC). The more abundant products could be isolated by liquid chromatography and their molecular weights determined by Mass Spectrometry (MS). Their structures, established according to their spectroscopic data, were compared to those of either the literature or of authentic samples. Thus lansoprazole led mainly to a mixture of 3H-benzimidazole-2-thione (2a) and 3H-benzimidazole-2-one (2c), omeprazole mainly to a mixture of 5-methoxy-3H-benzimidazole-2-thione (1a) and 2-hydroxymethyl-3, 5-dimethyl- 4-methoxypyridine (1b), and pantoprazole, to 5-difluoromethoxy-3H-benzimidazole-2-thione (3a) and 2-hydroxymethyl-3, 4-dimethoxypyridine (3b). Although some of the degradation products had already been observed under different conditions, the detection of benzimidazole-2- thiones is unprecedented and their involvement as possible physiological, yet toxic antioxidants must be emphasized. Plausible, unified mechanisms for the formation of the different degradation products observed herein and in previous papers from the literature are suggested.

Structure-activity relationship of 2-[[(2-Pyridyl)methyl]thio]-1H- benzimidazoles as anti Helicobacter pylori agents in vitro and evaluation of their in vivo efficacy

A relationship between the structure of 21 2-[[(2-pyridyl)methyl]thio]- 1H-benzimidazoles (6) and their anti Helicobacter pylori activity expressed as minimum bactericidal concentration (MBC) values is described. Observed MBCs ranged from 256 to 1 μg/mL. The structure - activity relationship (SAR) showed that larger and more lipophilic compounds, especially compounds with such substituents in the 4-position of the pyridyl moiety, generally had lower MBC values. Four new compounds 'that were predicted to be potent by the established SAR model were synthesized and tested. One such compound, i.e., 2-[[(4-[(cyclopropylmethyl)oxy]3-methyl-2-pyridyl)methyl]thio]-1H- benzimidazole (18), was tested for in vivo efficacy in a mouse Helicobacter felis model (125 μmol/kg bid given orally for 4 days, n = 4). Unfortunately, antibacterial activity could not be clearly demonstrated in this model. Instead a potent acid secretion inhibition was observed. This finding was attributed to the methylthio compound being oxidized to the corresponding methyl sulfinyl derivative, i.e., a proton pump inhibitor, in vivo. Although the antibacterial activity had the potential of decreasing H. felis cell counts in vivo the proton pump inhibitory effect became dominant and actually promoted H. felis cell growth. Hence, we conclude that the antibacterial utility of the 2-[[(2-pyridyl)methyl]thio]1H-benzimidazoles (6) as a compound class is compromised by their propensity to become proton pump inhibitors upon metabolic oxidation in vivo.